Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Harvard Business School
Boehringer Ingelheim
McKesson
Merck

Last Updated: January 26, 2023

Investigational Drug Information for GLPG1205


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for GLPG1205?

GLPG1205 is an investigational drug.

There have been 7 clinical trials for GLPG1205. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2014.

The most common disease conditions in clinical trials are Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonias, and Fibrosis. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].

There are seven US patents protecting this investigational drug and one hundred and twenty international patents.

Recent Clinical Trials for GLPG1205
TitleSponsorPhase
Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205Galapagos NVPhase 1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male SubjectsGalapagos NVPhase 1
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)Galapagos NVPhase 2

See all GLPG1205 clinical trials

Clinical Trial Summary for GLPG1205

Top disease conditions for GLPG1205
Top clinical trial sponsors for GLPG1205

See all GLPG1205 clinical trials

US Patents for GLPG1205

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GLPG1205 See Plans and Pricing Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (Mechelen, BE) See Plans and Pricing
GLPG1205 See Plans and Pricing Pyrrolo[1,2-b]pyridazine derivatives Gilead Sciences, Inc. (Foster City, CA) See Plans and Pricing
GLPG1205 See Plans and Pricing 2-oxindole compounds ChemoCentryx, Inc. (Mountain View, CA) See Plans and Pricing
GLPG1205 See Plans and Pricing 2-oxindole compounds ChemoCentryx, Inc. (Mountain View, CA) See Plans and Pricing
GLPG1205 See Plans and Pricing Pyrrolo[1,2-B]pyridazine derivatives Gilead Sciences, Inc. (Foster City, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GLPG1205

Drugname Country Document Number Estimated Expiration Related US Patent
GLPG1205 Argentina AR089284 2031-12-22 See Plans and Pricing
GLPG1205 Australia AU2012357067 2031-12-22 See Plans and Pricing
GLPG1205 Brazil BR112014015142 2031-12-22 See Plans and Pricing
GLPG1205 Canada CA2859578 2031-12-22 See Plans and Pricing
GLPG1205 Chile CL2014001664 2031-12-22 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Harvard Business School
Boehringer Ingelheim
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.